Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate CancerChristopher J. Sweeney, Robert S. DiPaola, Manish Kohli et al.|New England Journal of Medicine|2015Cited by 2.8k
Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer: Long-Term Survival Analysis of the Randomized Phase III E3805 CHAARTED TrialChristos E. Kyriakopoulos, Christopher J. Sweeney, Yu‐Hui Chen et al.|Journal of Clinical Oncology|2018Cited by 1.1k
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trialKarim Fizazi, Mika Mustonen, Christophe Massard et al.|The Lancet Oncology|2014Cited by 194
Clinical activity of nivolumab in patients with non-clear cell renal cell carcinomaVadim S. Koshkin, Brian I. Rini, Pedro C. Barata et al.|Journal for ImmunoTherapy of Cancer|2018Cited by 184